CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI; The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days D

Roxana Mehran,

Press/Media

Period	17 Oct 2020

Media coverage

9

Media coverage

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI; The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days D
Media name/outlet	PR Newswire
Country/Territory	United States
Date	17/10/20
Persons	Roxana Mehran,

Title CeloNova Announces Late-Breaking Evidence from...
Media name/outlet ADVFN Deutschland
Country/Territory Germany
Date 17/10/20
URL de.advfn.com/p.php?pid=nmona&article=83480202
Persons Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	PR Newswire European (Top News)
Country/Territory	United Kingdom
Date	17/10/20
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	Global English (Middle East and North Africa Financial Network)
Country/Territory	Jordan
Date	17/10/20
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	PR Newswire
Country/Territory	United States
Date	17/10/20
URL	https://www.prnewswire.com/news-releases/celonova-announces-late-breaking-evidence-from-first-ever-randomized-controlled-trial-evaluating-14-days-dapt-in-complex-patients-at-high-bleeding-risk-following-pci-301154350.html
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	TickerTech.com
Country/Territory	United States
Date	17/10/20
URL	www.tickertech.com/cgi/?a=news&ticker=a&w=&story=202010202010171652PR_NEWS_USPR_____DA61848
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	ProfitQuotes.com
Country/Territory	United States
Date	17/10/20
URL	www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=202010202010171652PR_NEWS_USPR_____DA61848
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	WFMZ-TV Online
Country/Territory	United States
Date	17/10/20
URL	https://www.wfmz.com/news/pr_newswire/pr_newswire_health/celonova-announces-late-breaking-evidence-from-first-ever-randomized-controlled-trial-evaluating-14-days-dapt/article_9a8f8ff4-db81-50b0-9c01-63ef4c2ec0ea.html
Persons	Roxana Mehran,

Title	CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
Media name/outlet	VB Profiles
Country/Territory	United States
Date	17/10/20
URL	https://www.vbprofiles.com/press_releases/5f8b5c7db9abe42b16d7af50
Persons	Roxana Mehran,